Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + melphalan + prednisone + thalidomide
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
The combination of bortezomib, melphalan, prednisone, and thalidomide (commonly abbreviated as VMPT) is a four-drug regimen used primarily in the treatment of multiple myeloma, especially for patients who are not eligible for autologous stem cell transplantation. Bortezomib is a proteasome inhibitor that disrupts protein degradation in cancer cells; melphalan is an alkylating agent that crosslinks DNA; prednisone is a corticosteroid with anti-inflammatory and immunosuppressive effects; and thalidomide has immunomodulatory and anti-angiogenic properties. Together, these agents act synergistically to increase response rates and prolong progression-free survival compared to regimens without all four drugs. Clinical trials have shown that VMPT followed by maintenance therapy with bortezomib-thalidomide improves complete response rates, progression-free survival, and overall survival in newly diagnosed multiple myeloma patients who are transplant-ineligible[1][2][3][4][8].
- Other names
- VMPT
02
Targets
CRBN (Cereblon)DNAGR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on bortezomib + melphalan + prednisone + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + melphalan + prednisone + thalidomide.